Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Inflammation is linked to cancer development, but its role in immunotherapy and chemotherapy outcomes is unclear.
• CMTM4 (CKLF-like MARVEL transmembrane domain-containing member 4) is highly expressed in various cancers.

Purpose of the Study:

• To investigate the role of CMTM4 in tumor growth, inflammation, and response to cancer therapies.
• To explore CMTM4 as a potential therapeutic target for enhancing immunotherapy and chemotherapy.

Main Methods:

• Studied CMTM4 expression in human and murine cancer models (Lewis lung carcinoma, triple-negative mammary cancer, melanoma).
• Utilized CMTM4 knockout models to assess tumor growth, pathway activation (NF-κB, mTOR, PI3K/Akt), and EGF signaling.
• Investigated CMTM4's role in EGFR recycling and degradation.
• Administered CMTM4-targeting siRNA-loaded liposomes in vivo.
• Evaluated the impact of CMTM4 knockout on immune checkpoint blockade and chemotherapy efficacy.

Main Results:

• CMTM4 knockout reduced tumor growth and impaired key cancer-promoting pathways.
• CMTM4 regulates EGF receptor (EGFR) recycling, sensitizing cells to EGFR inhibitors.
• CMTM4 knockout decreased inflammatory cytokine production and myeloid-derived suppressor cell recruitment, creating a less suppressive tumor microenvironment.
• CMTM4-targeting siRNA liposomes reduced tumor growth and prolonged survival.
• CMTM4 knockout enhanced the efficacy of immune checkpoint blockade and chemotherapy.

Conclusions:

• CMTM4 is a novel target for inhibiting tumor inflammation and improving anti-cancer immune responses.
• Targeting CMTM4 can enhance the sensitivity of tumors to chemotherapy and immunotherapy.
• Reducing CMTM4 levels offers a potential strategy to improve cancer treatment outcomes.